We prefer anakinra over canakinumab, due to increased risk of infections during pregnancy [177] and possible incidents of pregnancy complications, conditions that may require an abrupt termination of IL-1 blockers and therefore favor one with short half-life. The gene discussed is IL1B; the disease is infection.